anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a health management system, an information processing unit, a health management method and a control program capable of securely contributing to the health management of a user.  <P>SOLUTION: In a mobile terminal, a health management information acquisition means acquires health management information, including biometric information and exercise information of the user. A health management information transmission means transmits the health management information to the information processing unit via a network. In the information processing unit, a health management information storage means stores the received health management information of the user. A meal menu information generation means generates a meal menu of the user based on the health management information. A meal supply source information supply means supplies meal supply source information corresponding to the user to the mobile terminal, based on the meal menu generated by the meal menu information generation means and the supply source information stored in the meal supply source information storage means.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Both monocytes and macrophages are heterogeneous populations. It was traditionally understood that Ly6Chi classical (inflammatory) monocytes differentiate into pro-inflammatory Ly6Chi macrophages. Accumulating evidence has suggested that Ly6Chi classical monocytes can also differentiate into Ly6Clo pro-resolving macrophages under certain conditions, while their differentiation trajectory remains to be fully elucidated. The present study with scRNA-seq and flow cytometric analyses reveals that Ly6ChiPD-L2lo classical monocytes recruited to the allergic skin lesion sequentially differentiate into Ly6CloPD-L2hi pro-resolving macrophages, via intermediate Ly6ChiPD-L2hi macrophages but not Ly6Clo non-classical monocytes, in an IL-4 receptor-dependent manner. Along the differentiation, classical monocyte-derived macrophages display anti-inflammatory signatures followed by metabolic rewiring concordant with their ability to phagocytose apoptotic neutrophils and allergens, therefore contributing to the resolution of inflammation. The failure in the generation of these pro-resolving macrophages drives the IL-1α-mediated cycle of inflammation with abscess-like accumulation of necrotic neutrophils. Thus, we clarify the stepwise differentiation trajectory from Ly6Chi classical monocytes toward Ly6Clo pro-resolving macrophages that restrain neutrophilic aggravation of skin allergic inflammation.
This cohort will be an open label, randomized, 5 period, 5 treatment, 4 sequence, cross over single dose bioavailability study employing administration of four crizotinib formulations Treatments E, F, G and H (Crizotinib 250 mg dose Formulated Capsule and 250 mg dose crizotinib as prototypes 0.529 mg/mg, 0.470 mg/mg and 0.420 mg/mg Microspheres, respectively) in the fasted state to healthy adult subjects (Periods 1-4). In addition, Treatment I (250 mg dose of crizotinib OS) will be administered at Period 5, for a taste evaluation only (no pharmacokinetic (PK) sample collection after the dose), in the period immediately following the completion of Period 4 of Cohort 2. A Crizotinib Taste Assessment - Questionnaire for Cohort 2 will be filled by all subjects.
Patients receive veliparib orally every 12 hours on days 1-12, gemcitabine hydrochloride IV over 30 minutes on days 3 and 10, and cisplatin IV over 60-120 minutes on day 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with suspected or known germline BRCA mutations may continue to receive single-agent veliparib continuously in the absence of disease progression or unacceptable toxicity. Patients may undergo blood, tumor tissue, and hair follicle sample collection periodically for pharmacokinetic and correlative studies.
This is a multi-centre, randomized, open-label, flexible-titration, controlled, parallel-group study to investigate the safety and efficacy of a novel modified release formulation of oxcarbazepine (OXC MR) compared to an immediate release oxcarbazepine (OXC IR) product in patients with partial epilepsy. Adult patients of both gender, aged at least 18 years with refractory partial epilepsy, with or without secondary generalisation receiving a stable background treatment with daily dosages of exactly 900 or 1200 or 1500 mg Oxcarbazepine will be enrolled. Concomitant medication consisting of maximal 2 additional AEDs (vagus nerve stimulator included) is allowed and must be kept stable throughout the study. Patients, who agree to participate, will first sign and date the informed consent and undergo an evaluation at screening visit to determine eligibility. Those patients who qualify will be enrolled in the study, assigned a patient ID, and will enter the 4-week baseline period. Each patient will receive a seizure diary to record the number of seizures during the baseline period. For Visit 1 the patient will return to the clinic and complete all baseline procedures. Patients who have met the entry criteria will be randomised. The two treatment groups consist of 50 patients each, one group to be treated with OXC MR b.i.d. and the other to be treated with OXC IR b.i.d. in a 1:1 randomization. Following assignment to one of both treatment groups the patient will enter the dose-titration phase. From Visit 1 (Study Day 1) a total daily dose of 1200 mg /1500 mg /1800 mg oxcarbazepine will be given to the randomised patients. From Day 6 the dosage will be titrated to a maximum total daily dose of 2700 mg in steps of 300 mg every 6th day. Patients who experienced intolerable adverse events could reduce their daily dose by 150 mg on the 2nd day of up-titration for the remainder of the treatment period. In case the reduced dosage will also not be tolerated, in a second step the dosage can be reduced by further 150 mg OXC. The maximal tolerated dose achieved on up-titration will be maintained up to the final visit (Study Day 26).
Non-pharmacological treatments are recommended as first-line management in knee osteoarthritis. Kinesiotape was regarded as a supplementary intervention for patients with knee osteoarthritis. Although the results are conflicting, regarding knee osteoarthritis, recently published studies indicate beneficial effects of kinesiotape on knee-related health status, pain, quadriceps muscle strength, and range of motion. On the other hand, the measurements were performed immediately following taping or within a short-term period. The inconsistency of the study data still indicates that the efficacy of kinesiotape in knee osteoarthritis should be evaluated in randomized controlled trials. Therefore a study that investigates both short and long-term follow-up results are warranted.

This study aimed to determine the immediate and long-term effects of the single and repetitive application of kinesiotape on pain, knee joint range of motion, postural stability, and physical performance in participants with knee osteoarthritis. The results of this study will support evidence-based reports based on the effectiveness of kinesiotape in knee osteoarthritis and recommendations for future studies.
Neuropsychiatric conditions are increasingly being understood as disorders of intrinsic, functional interactions within and between widespread, distributed, brain networks. Given recent advances in functional Magnetic Resonance Imaging (fMRI) data acquisition and computational analysis, it is now possible to reliably map the functional neuroanatomy of brain networks within individuals, offering a potential avenue for identifying personalized neurotherapeutic targets. However, gold standard treatments (e.g. pharmacotherapy) in current psychiatric practice were not originally designed to target specific brain network interactions and lack protocols that leverage such individual-level data. Real-time neurofeedback- whereby patients observe and learn to regulate selected aspects of their own brain activity- is a candidate approach to personally tailor the normalization of unhealthy communication within and between brain networks. However, to target the major brain networks that function abnormally in neuropsychiatric conditions, neurofeedback relies on fMRI, which is an expensive procedure involving a complex setup and patient burden. The goal of this project is to develop an electroencephalography (EEG) "fingerprint" of fMRI network dynamics so that a neurofeedback system based on EEG (electrodes placed on the scalp) alone can be used to precisely target interactions within and between brain networks. Because EEG devices can be portable and offer relatively simple setup in flexible settings, this research could enable a scalable form of network-based neurofeedback training that patients could regularly access. Aim 1 of this research is identify an optimal model of EEG features that are predictive of fMRI-based default mode network (DMN) "antagonism" within individuals. The investigators focus on this DMN antagonism because it is a major feature that is relevant to cognitive dysfunction in psychiatry disease at a transdiagnostic level. The investigators will collect high-quality, simultaneous EEG-fMRI data in 24 healthy adults (\>100 mins of sampling per participant), including three conditions: (1) resting state, (2) continuous task performance, and (3) continuous fMRI-based neurofeedback from DMN antagonism states. The investigators will apply machine learning-based methods to identify an optimal mapping between EEG signal components and fMRI-based DMN antagonism. Further, the investigators will determine how much individual-level EEG-fMRI sampling is needed to successfully predict DMN antagonism from EEG. Aim 2 of the research is to test whether EEG markers of DMN antagonism are predictive of cognitive task performance fluctuations within individuals. As such, the findings could offer validation of the behavioral relevance of an EEG neurofeedback system that would target DMN antagonism. If successful, the work can lead to development of an accessible, computational psychiatry tool that can be tested in clinical conditions in which DMN antagonism (and related cognitive function) is affected, including attention-deficit/hyperactivity disorder, depression and schizophrenia.
A group of 34 subjects will be scanned on a 3Tesla (3T) and on a 7T MRI scanner. The images will be compared.
Received Placebo three times daily orally or via gastric tube with meals, then EPI-743, 15mg/kg up to a maximum dose of 200 mg three times daily orally or via gastric tube with meals. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
Micronutrients (MN), i.e. trace elements and vitamins, are essential components of the diet in relatively small amounts in any form of nutrition, with special needs in critically ill patients. Critical illness is characterised by the presence of inflammation and oxidative stress. MNs are tightly involved in antioxidant and immune defences. In addition, some conditions, and treatments result in large losses of biological fluids containing MNs: therefore, acute renal injury requiring renal replacement therapy, acute intestinal failure, and major burns and trauma are at high risk of acute depletion of body stores, and of deficiency. MN requirements are increased above standard DRI. Blood level interpretation is complicated by inflammation: some biomarkers assist the status determination. Due to the acute challenges of critical illness, it of utmost importance to cover the needs to maintain the organism's endogenous immune and antioxidant defences, and capacity to repair tissues. Practical strategies are proposed.
The invention belongs to the technical field of natural medicines, and in particular relates to application of selaginella total flavonoids in preparing medicines for treating hyperuricemia. The invention provides an application of selaginella total flavone in preparing a medicament for treating hyperuricemia. The invention researches the action and mechanism of the selaginella total flavone in reducing uric acid. The test result shows that the selaginella total flavone can obviously reduce uric acid by inhibiting xanthine oxidase, thereby improving the corresponding symptoms of hyperuricemia, including gout caused by hyperuricemia. In addition, the selaginella total flavone has the characteristics of remarkable effect and small toxic and side effects in reducing uric acid. The application of the invention can provide medicine selection for preparing hyperuricemia medicines, provide scientific and strict experimental evidence for the aspect of treating hyperuricemia for selaginella tamariscina total flavone, and lay a working foundation for clinical medicine development.
To solve problems associated with a formulation containing a tranexamic acid and ibuprofen in which the formulation is unstable and volume of the formulation expands.SOLUTION: A formulation contains ibuprofen and a tranexamic acid, the formulation comprising particulate powder in which a mixture containing ibuprofen and tranexamic acid is coated with a saccharine layer of sugar alcohols or saccharides. A method for producing a formulation containing ibuprofen and tranexamic acid includes a spraying step, a granulating step, and a drying step. In the spraying step, a mixture containing ibuprofen and tranexamic acid is sprayed with a saccharine solution of sugar alcohols or saccharides. In the granulating step, the sprayed mixture is subjected to fluidized bed granulation. In the drying step, the powder having been subjected to fluidized bed granulation is dried for use in the formulation. This can suppress expansion of the formulation without the need for complicated steps like the conventional art.SELECTED DRAWING: Figure 9
A system and method for studying a test subject includes monitoring the test subject as it traverses through a programmable maze. The test subject may be under the influence of experimental drugs or genetic manipulation. The dynamic maze can be changed automatically or manually to test the abilities of the test subject. The dynamic maze comprises of a starting point, an ending point, and an electronically programmable floor capable of constructing various obstacles and passageways. The programmable floor may be programmed by a human user using an interface, or it may be programmed by an automated control system that programs the maze in accordance with the ability of the test subject to traverse the maze. Various devices are incorporated with the use of the maze to monitor the activities and welfare of the test subject.
An advanced biometric bracelet has been designed that can monitor vital signs in emergencies and critical situations. Thanks to facial recognition technology, this bracelet records, displays, and sends the patient's data to the doctor. In situations where the number of patients or clients to hospitals and medical centers is high, or in case of natural disasters, this bracelet can alleviate probable risks by shortening the waiting time of patients. Equipped with biometric sensors, this bracelet can record vital signs including blood oxygen level, heart rate, and body temperature. In emergencies, the bracelet will alert and store the data for a while so that the doctor can check for fluctuations. The camera mounted on the bracelet helps to save the changes in the patient's face in the memory of the device and transmit it to the doctor via Wi-Fi.
A composition for enhancing protein anabolism and detoxification comprises molybdenum and at least two amino acids selected from the group consisting of L-arginine, L-cystine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-tyrosine, and L-valine. Preferably the composition further comprises creatine and/or sulfur. Preferably the amino acids are all free form amino acids. The composition is provided in the form of a powder, which is preferably encapsulated in a gelatin capsule. Methods for enhancing protein anabolism and/or detoxification in a patient comprise administering to the patient an effective amount of a composition as described above. The composition is preferably administered orally in an amount of from about 3 grams/day to about 10.5 grams/day.
INFUMORPH (preservative-free morphine sulfate sterile solution) is an opioid agonist, available as a sterile, nonpyrogenic, isobaric, high potency solution of morphine sulfate in strengths of 10 mg or 25 mg morphine sulfate per mL, free of antioxidants, preservatives or other potentially neurotoxic additives. INFUMORPH is intended for use in continuous microinfusion devices for intraspinal administration in the management of pain. Morphine is the most important alkaloid of opium and is a phenanthrene derivative. It is available as the sulfate salt, chemically identified as 7,8-Didehydro-4,5- epoxy-17- methyl-(5α,6α)-morphinan-3,6-diol sulfate (2:1) (salt), pentahydrate, with the following structural formula:

(C17H19NO3)2 • H2SO4 • 5H2O Molecular Weight is 758.83

Morphine sulfate USP is an odorless, white crystalline powder with a bitter taste. It has a solubility of 1 in 21 parts of water and 1 in 1000 parts of alcohol, but is practically insoluble in chloroform or ether. The octanol:water partition coefficient of morphine is 1.42 at physiologic pH and the pKa is 7.9 for the tertiary nitrogen (the majority is ionized at pH 7.4).

Each mL of INFUMORPH 200 contains morphine sulfate, USP 10 mg (200 mg/20 mL) and sodium chloride 8 mg in Water for Injection, USP. Each mL of INFUMORPH 500 contains morphine sulfate, USP 25 mg (500 mg/20 mL) and sodium chloride 6.25 mg in Water for Injection, USP. If needed, sodium hydroxide and/or sulfuric acid are added for pH adjustment to 4.5. Contains no preservative. Each 20 mL ampul of INFUMORPH is intended for SINGLE USE ONLY.
Dextrose Injection 70%, USP is a clear, sterile, nonpyrogenic, hypertonic solution of Dextrose, USP in Water for Injection in a flexible plastic container as a Pharmacy Bulk Package. A Pharmacy Bulk Package is a container of a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program. Dextrose Injection is not for direct intravenous infusion [see Dosage and Administration (2.1)]. 

The Pharmacy Bulk Package is designed to facilitate admixture or dilution to provide dextrose in various concentrations and is available in a 2000 mL size. See Table 1 for the content and characteristics of this solution.

The solution contains no bacteriostatic, antimicrobial agent or added buffer and is intended only for use following admixture or dilution. The pH range is 4.0 (3.2 to 6.5).

Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly.

Dextrose, USP is chemically designated D-glucose, monohydrate (C6H12O6 • H2O), a hexose sugar freely soluble in water. The molecular weight of dextrose (D-glucose) monohydrate is 198.17. It has the following structural formula:

Water for Injection, USP is chemically designated H2O.

Dextrose Injection 70%, USP contains no more than 25 mcg/L of aluminum.

Dextrose is derived from corn.
The invention discloses thiamphenicol granules and a preparing method thereof. The granules comprise, by weight, 1%-50% of thiamphenicol, 45%-99% of thiamphenicol adsorption carriers and 0.05%-4% of thiamphenicol sorbefacients. The method comprises the following steps that the material is prepared according to the components, the thiamphenicol, the thiamphenicol adsorption carriers and the thiamphenicol sorbefacients are mixed evenly, thiamphenicol powder is prepared, adhesives are sprayed to a fluidized bed, and granulation is conducted. The preparing method is simple and low in cost. The thiamphenicol granules have the advantages that in-vitro release speed is high, internal absorption speed is high, blood peak concentration is high, medicine is absorbed completely, and few antibiotics are left. The thiamphenicol granule can be used for treating infection of every part of the whole body of livestock and poultry caused by bacteria.
GSH-FBT consists of 10 20-minute parent-only sessions over 9 months. The guidance portion is manualized and will be delivered by a clinician familiar with both the online modules and FBT, who acts as a "coach." Sessions follow an online curriculum containing a total of 65 short videos. Each lecture series is comprised of a written introduction orienting the viewer to the videos, 5-9 short videos (\< 7 minutes each), and assigned reading from the parent education manual, Help Your Teenager Beat an Eating Disorder. In line with GSH approaches, coaches direct parents to watch or re-watch specific videos contained in the online platform related to their questions.
Cancers of gastrointestinal tract make up the largest group of solid tumour diseases in Germany. The prognosis at diagnosis is often critical. Drug therapies reduce the risk of relapse after resection and can halt the progression of metastatic disease. Immunotherapies contribute increasingly to the treatment of gastrointestinal tumours. Monoclonal antibodies (mAB) against surface receptors from the epidermal growth factor receptor family (EGFR, Her2) are well established. The effect is partly based on the interruption of the oncogenic downstream signalling cascades and partly on immune effector mechanisms such as antibody-dependent cellular cytotoxicity. In clinical practice mAB directed against programmed cell death protein 1 (PD-1), its ligand (PD-L1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) - so-called immune checkpoint inhibitors - play an increasing role and change the natural history of some subgroups of gastrointestinal cancers, especially those with deficient DNA mismatch repair which leads to genomic microsatellite instability.
INTRODUCTION: Striae distensae are a permanent skin defect that can affect 50%-90% of the population. The appearance of the changes resembles spindle-shaped skin bands. The skin in this area is wrinkled, thin and looks like a scar. Most often, the changes are found on the skin of the abdomen, buttocks, breasts, thighs, and back. The appearance of striae means that the skin in this area has no hair follicles, sebaceous, and sweat glands. This skin is flabby, not very elastic and, what is very characteristic, the pigmentation of the skin affected by striae is much lower than in healthy skin. Cosmetology in the 21st century is developing very dynamically, new technologies are being developed, new cosmetological devices are being created and combined with treatments that have been known for a long time. Today's science offers hope for people who have struggled with reducing striae for many years and nowadays, nothing is impossible.
AIMS: The objective of this article is to provide information about cosmetological treatment used to reduce striae.
METHODS: In this article, we reviewed the published literature, article published in peer-reviewed journals.
RESULTS: Today's cosmetology offers a wide range of numerous treatments, but the best results are achieved through a synergy of two or more treatments. But we should not forget that we should respond to each customer individually.
CONCLUSION: The striae are not a problem that should be ignored. The beauty therapist is able to reduce them and help the client to improve the appearance of their skin.